Sevuparin

Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.

Learn more

Sickle Cell Disease

An orphan disease with large unmet medical need.

Learn more

Modus Therapeutics appoints Ellen K. Donnelly, Ph.D. as CEO

Modus Therapeutics raises SEK 32 million to support further development of sevuparin for sickle cell disease

Sevuparin blocks sickle blood cell adhesion and sickle leukocyte rolling on immobilized L-selectin in a dose-dependent manner

Sevuparin demonstrates binding to key adhesion receptors involved in pathogenesis of Sickle Cell Disease

What’s going on at Modus Therapeutics

Modus’ CEO, Christina Herder, to present the company at the 5th Annual Sickle Cell Disease Therapeutics Conference in New York.

Modus Therapeutics to present at SCD Therapeutics Conference in New York

Modus’ CEO, Christina Herder, presented the company at the 5th Annual Sickle Cell Disease Therapeutics.

Modus Therapeutics to present at SCD Therapeutics Conference in New York

In her presentation, Dr Herder will outline Modus Therapeutics’s development plans for sevuparin, a novel drug that it believes could offer a significant improvement of treatments in SCD.

Modus Therapeutics poster presentation at EHA Congress

Modus Therapeutics’s submission is entitled: ‘Sevuparin Demonstrates Binding to Key Adhesion Receptors Involved in Pathogenesis of Sickle-Cell Disease’.